For premenopausal women , discussion should cover: Contraceptive reliability and the need for additional precautions or alternative methods The possibility of improved fertility with weight loss, particularly in women with PCOS or obesity-related subfertility Monitoring for menstrual cycle changes, which may indicate improving metabolic health Pregnancy planning, as Mounjaro should be discontinued at least one month before conception according to the UK product information, and should be avoided during pregnancy and breastfeeding Risk of hypoglycaemia if also taking insulin or sulfonylureas, which may require dose adjustments of these medications For perimenopausal and postmenopausal women , considerations include: Potential reduction in peripheral oestrogen production with significant weight loss Monitoring for changes in menopausal symptoms Continued appropriateness of hormone replacement therapy (HRT) if already prescribed, noting that Mounjaro does not contraindicate HRT use Consider non-oral HRT routes if significant gastrointestinal symptoms occur Women with hormone-sensitive conditions such as oestrogen-receptor-positive breast cancer history, endometriosis, or uterine fibroids should discuss Mounjaro use with their oncologist or specialist
The most commonly cited starting protocol in the medical literature and clinical practice involves 250 micrograms administered once daily for acute injury, stepping up to 500 micrograms daily if response is insufficient after one to two weeks
1 mL (6 pumps) provides a concentrated blend of ingredients shown to enhance the quality, duration and impact of your sleep
Supplementation with NAD+ precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) raises intracellular NAD+ concentrations and activates sirtuins
Specification: State of solution: Clear and colorless
